These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1098 related articles for article (PubMed ID: 18227474)

  • 1. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 4. Insulin in the early management of diabetic complications.
    Miles JM
    J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
    Tattersall RB
    Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219
    [No Abstract]   [Full Text] [Related]  

  • 7. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
    Goo AK; Carson DS; Bjelajac A
    J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin initiation in Type 2 diabetes.
    Page S
    Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus.
    Ravipati G; Aronow WS; Ahn C; Sujata K; Saulle LN; Channamsetty V; Weiss MB
    Am J Ther; 2006; 13(5):400-3. PubMed ID: 16988534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Knack of treatment with oral hypoglycemic drugs in the elderly].
    Komatsu M; Hashizume K
    Nihon Rinsho; 2006 Jan; 64(1):93-8. PubMed ID: 16408454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating type 2 diabetes: targeting the many causative factors.
    Sutherland JE; Hoehns JD
    J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P
    Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choosing first-line therapy for management of type 2 diabetes.
    Graber MA; Darby-Stewart A; Dachs R
    Am Fam Physician; 2008 Jan; 77(1):16-7. PubMed ID: 18236820
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
    Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
    Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
    Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
    Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hardly any hypoglycemias, constant weight--and still cost effective].
    MMW Fortschr Med; 2005 Nov; 147(47):72-3. PubMed ID: 16370200
    [No Abstract]   [Full Text] [Related]  

  • 19. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
    MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
    [No Abstract]   [Full Text] [Related]  

  • 20. beta-cell function and anti-diabetic pharmacotherapy.
    Del Prato S; Bianchi C; Marchetti P
    Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.